Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and
highest safe dose of this drug when administered intravenously weekly for three weeks of a
four week cycle in patients with advanced solid tumors.